Cargando…
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
On 7 June(,) the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350893/ https://www.ncbi.nlm.nih.gov/pubmed/34338436 http://dx.doi.org/10.15252/emmm.202114781 |